Vascular Biogenics Ltd (NASDAQ:VBLT) was the target of a significant growth in short interest in February. As of February 14th, there was short interest totalling 107,200 shares, a growth of 104.2% from the January 30th total of 52,500 shares. Approximately 0.4% of the shares of the stock are sold short. Based on an average daily volume of 94,000 shares, the short-interest ratio is currently 1.1 days.
Large investors have recently made changes to their positions in the company. Morgan Stanley increased its holdings in shares of Vascular Biogenics by 6.5% in the second quarter. Morgan Stanley now owns 295,012 shares of the biopharmaceutical company’s stock worth $383,000 after buying an additional 17,900 shares during the period. PVG Asset Management Corp bought a new stake in shares of Vascular Biogenics in the 4th quarter valued at about $48,000. Finally, Renaissance Technologies LLC lifted its stake in shares of Vascular Biogenics by 81.6% in the 4th quarter. Renaissance Technologies LLC now owns 35,615 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 16,003 shares during the last quarter. 4.10% of the stock is currently owned by hedge funds and other institutional investors.
Several brokerages have issued reports on VBLT. Chardan Capital reaffirmed a “buy” rating and set a $3.25 price target on shares of Vascular Biogenics in a research note on Friday, January 10th. Zacks Investment Research upgraded Vascular Biogenics from a “hold” rating to a “buy” rating and set a $1.75 price objective on the stock in a research report on Tuesday, January 28th. ValuEngine raised Vascular Biogenics from a “sell” rating to a “hold” rating in a report on Thursday, February 6th. HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of Vascular Biogenics in a research report on Friday, November 15th. Finally, Roth Capital reaffirmed a “buy” rating on shares of Vascular Biogenics in a research note on Thursday, January 2nd. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $2.50.
About Vascular Biogenics
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.
Recommended Story: Why do analysts give a neutral rating?
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.